These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

425 related items for PubMed ID: 31167663

  • 1. Canagliflozin for Japanese patients with chronic heart failure and type II diabetes.
    Sezai A, Sekino H, Unosawa S, Taoka M, Osaka S, Tanaka M.
    Cardiovasc Diabetol; 2019 Jun 05; 18(1):76. PubMed ID: 31167663
    [Abstract] [Full Text] [Related]

  • 2. Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.
    Tanaka A, Toyoda S, Imai T, Shiina K, Tomiyama H, Matsuzawa Y, Okumura T, Kanzaki Y, Onishi K, Kiyosue A, Nishino M, Sakata Y, Node K, CANDLE trial investigators.
    Cardiovasc Diabetol; 2021 Sep 03; 20(1):175. PubMed ID: 34479543
    [Abstract] [Full Text] [Related]

  • 3. Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial.
    Kusunose K, Imai T, Tanaka A, Dohi K, Shiina K, Yamada T, Kida K, Eguchi K, Teragawa H, Takeishi Y, Ohte N, Yamada H, Sata M, Node K, CANDLE Trial Investigators.
    Cardiovasc Diabetol; 2021 Sep 14; 20(1):186. PubMed ID: 34521417
    [Abstract] [Full Text] [Related]

  • 4. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program.
    Rådholm K, Figtree G, Perkovic V, Solomon SD, Mahaffey KW, de Zeeuw D, Fulcher G, Barrett TD, Shaw W, Desai M, Matthews DR, Neal B.
    Circulation; 2018 Jul 31; 138(5):458-468. PubMed ID: 29526832
    [Abstract] [Full Text] [Related]

  • 5. Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus.
    Figtree GA, Rådholm K, Barrett TD, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Matthews DR, Shaw W, Neal B.
    Circulation; 2019 May 28; 139(22):2591-2593. PubMed ID: 30882240
    [No Abstract] [Full Text] [Related]

  • 6. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes.
    Matsutani D, Sakamoto M, Kayama Y, Takeda N, Horiuchi R, Utsunomiya K.
    Cardiovasc Diabetol; 2018 May 22; 17(1):73. PubMed ID: 29788955
    [Abstract] [Full Text] [Related]

  • 7. Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study.
    Tamaki S, Yamada T, Watanabe T, Morita T, Furukawa Y, Kawasaki M, Kikuchi A, Kawai T, Seo M, Abe M, Nakamura J, Yamamoto K, Kayama K, Kawahira M, Tanabe K, Fujikawa K, Hata M, Fujita Y, Umayahara Y, Taniuchi S, Sanada S, Shintani A, Fukunami M.
    Circ Heart Fail; 2021 Mar 22; 14(3):e007048. PubMed ID: 33663235
    [Abstract] [Full Text] [Related]

  • 8. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis.
    Yu YW, Zhao XM, Wang YH, Zhou Q, Huang Y, Zhai M, Zhang J.
    Cardiovasc Diabetol; 2021 Jan 25; 20(1):25. PubMed ID: 33494751
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.
    Tanaka H, Soga F, Tatsumi K, Mochizuki Y, Sano H, Toki H, Matsumoto K, Shite J, Takaoka H, Doi T, Hirata KI.
    Cardiovasc Diabetol; 2020 Jan 07; 19(1):6. PubMed ID: 31910853
    [Abstract] [Full Text] [Related]

  • 11. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.
    Hiruma S, Shigiyama F, Hisatake S, Mizumura S, Shiraga N, Hori M, Ikeda T, Hirose T, Kumashiro N.
    Cardiovasc Diabetol; 2021 Feb 02; 20(1):32. PubMed ID: 33530982
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
    Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, Fulcher G, Desai M, Li Q, Deng H, Rosenthal N, Jardine MJ, Bakris G, Perkovic V.
    Circulation; 2018 Oct 09; 138(15):1537-1550. PubMed ID: 29941478
    [Abstract] [Full Text] [Related]

  • 14. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus.
    Carbone S, Dixon DL.
    Cardiovasc Diabetol; 2019 May 28; 18(1):64. PubMed ID: 31138195
    [Abstract] [Full Text] [Related]

  • 15. The plasma levels of atrial natriuretic peptide and brain natriuretic peptide in type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor.
    Feng X, Gu Q, Gao G, Yuan L, Li Q, Zhang Y.
    Ann Endocrinol (Paris); 2020 Oct 28; 81(5):476-481. PubMed ID: 32822653
    [Abstract] [Full Text] [Related]

  • 16. Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial.
    Takashima H, Yoshida Y, Nagura C, Furukawa T, Tei R, Maruyama T, Maruyama N, Abe M.
    Diab Vasc Dis Res; 2018 Sep 28; 15(5):469-472. PubMed ID: 29923427
    [Abstract] [Full Text] [Related]

  • 17. Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus.
    Ejiri K, Miyoshi T, Kihara H, Hata Y, Nagano T, Takaishi A, Toda H, Nanba S, Nakamura Y, Akagi S, Sakuragi S, Minagawa T, Kawai Y, Nishii N, Fuke S, Yoshikawa M, Nakamura K, Ito H, MUSCAT‐HF Study Investigators †.
    J Am Heart Assoc; 2020 Aug 18; 9(16):e015103. PubMed ID: 32805185
    [Abstract] [Full Text] [Related]

  • 18. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
    Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, Desai M, Matthews DR, CANVAS Program Collaborative Group.
    Circulation; 2018 Jan 23; 137(4):323-334. PubMed ID: 29133604
    [Abstract] [Full Text] [Related]

  • 19. The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction.
    Genuardi MV, Mather PJ.
    Ther Adv Cardiovasc Dis; 2021 Jan 23; 15():17539447211002678. PubMed ID: 33779401
    [Abstract] [Full Text] [Related]

  • 20. Role of Canagliflozin on function of CD34+ve endothelial progenitor cells (EPC) in patients with type 2 diabetes.
    Nandula SR, Kundu N, Awal HB, Brichacek B, Fakhri M, Aimalla N, Elzarki A, Amdur RL, Sen S.
    Cardiovasc Diabetol; 2021 Feb 13; 20(1):44. PubMed ID: 33581737
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.